Welcome to CDC stacks | The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients - 43926 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients
  • Published Date:
    Dec 23 2016
  • Source:
    Breast Cancer Res Treat. 161(3):587-595.


Public Access Version Available on: February 01, 2018 information icon
Please check back on the date listed above.
Details:
  • Pubmed ID:
    28012085
  • Pubmed Central ID:
    PMC5243200
  • Description:
    Purpose

    To quantify the influence of RS assay on changing chemotherapy plans in a general practice setting use using causal inference methods.

    Methods

    We surveyed 3,880 newly-diagnosed breast cancer patients in Los Angeles and Georgia in 2013-14. We used inverse propensity weighting and multiple imputations to derive complete information for each patient about treatment status with and without testing.

    Results

    Half of the 1,545 women eligible for testing (ER+ or PR+, HER2−, and stage I-II) received RS. We estimate that 30% (95% confidence interval (CI): 10% - 49%) of patients would have changed their treatment selections after RS assay, with 10% (CI: 0%-20%) being encouraged to undergo chemotherapy and 20% (CI: 10% -30%) being discouraged from chemotherapy. The subgroups whose treatment selections would be changed the most by RS were patients with positive nodes (44%; CI: 24% - 64%), larger tumor (43% for tumor size >2 cm; CI: 23% - 62%) or younger age (41% for <50 years, CI: 23% - 58%). The assay was associated with a net reduction in chemotherapy use by 10% (CI: 4% - 16%). The reduction was much greater for women with positive nodes (31%; CI: 21% - 41%), larger tumor (30% for tumor size >2 cm; CI: 22% - 38%) or younger age (22% for <50 years; CI: 9% - 35%).

    Conclusion

    RS substantially changed chemotherapy treatment selections with the largest influence among patients with less favorable pre-test prognosis. Whether this is optimal awaits the results of clinical trials addressing the utility of RS testing in selected subgroups.

  • Document Type:
  • Collection(s):
  • Funding:
    HHSN261201000035C/PC,CA/None/None
    HHSN261201000140C/CA/NCI NIH HHS/United States
    P01 CA163233/CA/NCI NIH HHS/United States
    U58 DP003875/DP/NCCDPHP CDC HHS/United States
    HHSN261201300015C/RC/CCR NIH HHS/United States
    HHSN261201000035I/CA/NCI NIH HHS/United States
    HHSN261201000034C/CA/NCI NIH HHS/United States
    U58 DP003862/DP/NCCDPHP CDC HHS/United States
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like: